Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
2'-Deoxyadenosine is a naturally occurring purine nucleoside composed of adenine linked to a deoxyribose sugar. It is a DNA component and plays central roles in genetic information storage and cellular metabolism. It is not itself considered a therapeutic target, but its metabolism is clinically significant; inborn errors (especially ADA deficiency) or pharmacological ADA inhibition lead to its accumulation and resulting immune suppression or toxicity. At excessive intracellular concentrations, particularly when ADA is absent, it induces cell death in lymphocytes and can contribute to immunodeficiency syndromes. In summary, 2'-deoxyadenosine is not a canonical drug target, but a physiologically important metabolite whose dysregulation is implicated in disease. Therapies focus on its metabolic enzymes (e.g., ADA), not the nucleoside itself.
In ADA deficiency or with ADA inhibitor treatment: accumulation of deoxyadenosine and associated metabolites is toxic to lymphocytes, primarily by interfering with DNA synthesis and repair, leading to apoptosis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 2'-Deoxyadenosine (dA, 2'-dA).